NONO and mucoepidermoid carcinoma: CRTC1–MAML2 fusion was a major oncogenic driver for mucoepidermoid carcinoma initiation and maintenance, CRTC1–MAML2 fusion remarkably up-regulated LINC00473 transcription to promote the binding to a cAMP signaling pathway component NONO and subsequently activate CREB-mediated transcription [12].